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Background: To examine the effects of type 2 diabetes mellitus (DM) on the variables associated with
prostatic growth including serum prostate-speciﬁc antigen (PSA), serum testosterone, and prostate
volume, and to correlate these variables with the duration of diabetes treatment.
Methods: Our study was conducted over 3 months recruiting 501 men aged 55 years; of whom 207
had type 2 DM. Exclusion criteria were active urinary tract infection, suspicious rectal examination,
urologic cancer, end-organ damage, and recent urological manipulations. Serum PSA and serum
testosterone were measured. Prostate volume was determined by abdominal ultrasonography using an
ellipsoid formula.
Results: The mean patient age was 60.21± 5.95 years. The mean PSA, testosterone, and prostate volume
for diabetic men were 2.3 ng/mL, 3 ng/mL, and 56 g, respectively. The corresponding values for nondi-
abetic men were 3.5 ng/mL, 4 ng/mL, and 51 g, respectively (P¼ 0.001, P¼ 0.001, P¼ 0.03, respectively).
The mean PSA density was 0.049± 0.043 ng/mL/cm3 in diabetics versus 0.080± 0.056 ng/mL/cm3 in non-
diabetics (P< 0.001).
Conclusion: Type 2 DM is signiﬁcantly associated with lower serum PSA and testosterone, and larger
prostate volume.
Copyright © 2016 Asian Paciﬁc Prostate Society, Published by Elsevier. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Diabetes mellitus (DM) is a serious problem in male health. A
positive association exists between clinical markers of benign
prostatic hyperplasia (BPH) and DM.1,2 Subnormal serum free
testosterone is detected in diabetic men.3 Kasper et al suggested an
inverse correlation between DM and the risk of prostate cancer.4
The aim of this work was to determine the effects of type 2 DM
on serum total prostate-speciﬁc antigen (PSA), serum total testos-
terone, and prostate volume.2. Materials and methods
The study was prospectively conducted over 3 months and
recruited male patients aged 55 years who presented to our
hospital with different benign urological conditions. The study
included 501 men and 207 of them had type 2 DM. Exclusionculty of Medicine, University
dria, Egypt.
.M. Hashad), drahmedfali@
ciﬁc Prostate Society, Published bcriteria were patients with active urinary tract infection, urological
cancer, end-organ damage, abnormal digital rectal examination
ﬁndings, and recent urological manipulations.
This study was approved by the ethical committee of our
institution and informed consent was obtained from participating
patients.
All men were subjected to detailed history taking and physical
examination. Body mass index was calculated. Six milliliters of
venous blood were drawn at 8:00 AM, then serum was separated
and stored at 20C. Serum PSA and testosterone were assessed
using electro-chemiluminescence immunoassay. Prostate size was
calculated using abdominal ultrasonography. The ellipsoid formula
was applied.
Data were analyzed using SPSS version 18.0 (SPSS, IBM Corpo-
ration, Chicago, IL, USA). The P value was assumed to be signiﬁcant
at  0.05.
3. Results
The mean age of patients was 60.21± 5.95 years (55.0e93.0
years). For diabetic patients, the mean PSA, testosterone, and
prostate volume were 2.3 ng/mL, 3 ng/mL, and 56 g, respectively.y Elsevier. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Comparison between the two studied groups according to PSA, testosterone, prostate volume, PSA density, and BMI.
Variable Diabetics (207) Nondiabetics (294) P value
PSA 2.3± 1.5 3.5± 1.9 0.001
PSA < 4 179 (86.5%) 193 (65.6%) < 0.0001
> 4 28 (13.5) 101 (34.4%)
Testosterone 3± 1.8 4± 2.1 0.001
Prostate volume 56± 18 51± 23 0.03
PSA density 0.05± 0.04 0.08± 0.05 0.001
BMI 32.23± 5.04 29.32± 4.20 0.001
BMI, body mass index; PSA, prostate-speciﬁc antigen.
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mL, 4 ng/mL and 51 g, respectively. The mean body mass index
(BMI) was 32.23± 5.04 and 29.32± 4.20 for diabetic patients and
nondiabetic individuals, respectively (Table 1).
There was a signiﬁcant positive correlation between duration of
treatment of DM and mean prostate volume (r¼ 0.147, P¼ 0.034)
(Fig. 1), while signiﬁcant negative correlations were found between0
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Fig. 2. Correlation between duration of treatment of diabetes melliduration of DM treatment and mean serum PSA values (r¼0.219,
P¼ 0.002) (Fig. 2), mean serum testosterone values (r¼0.221,
P¼ 0.001) (Fig. 3), and mean PSA density values (r¼0.203,
P¼ 0.003) (Fig. 4).
High BMI in diabetic patients was a confounding factor, there-
fore, multiple regression analysis was done, conﬁrming the true
signiﬁcant correlation of DMwith the studied parameters (Table 2).25 30 35 40 45
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Fig. 3. Correlation between duration of treatment of diabetes mellitus with testosterone in diabetic group.
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Fig. 4. Correlation between duration of treatment of diabetes mellitus with PSA density in diabetic group. PSA, prostate-speciﬁc antigen.
Table 2
Multiple regression analysis for PSA, testosterone, prostate volume and PSA density,
in relation to DM, studying BMI as a confounding factor
B SE t p 95% CI
Lower Upper
PSA DM 0.743 0.155 4.795* < 0.001 0.439 1.048
BMI 0.166 0.016 10.359* < 0.001 0.197 0.134
F¼ 87.977*, P< 0.001*, R¼ 0.511, R2¼ 0.261
Testosterone DM 0.400 0.165 2.420* 0.016 0.075 0.724
BMI 0.210 0.017 12.305* < 0.001 0.243 0.176
F¼ 96.237*, P< 0.001*, R¼ 0.528, R2¼ 0.279
Prostate volume DM 4.629 1.633 2.835* 0.005 1.420 7.837
BMI 3.011 0.168 17.883* < 0.001 2.680 3.341
F¼ 136.430*, P< 0.001*, R¼ 0.629, R2¼ 0.396
PSA density DM 0.020 0.004 4.853* < 0.001 0.012 0.028
BMI 0.006 0.000 14.784* < 0.001 0.007 0.005
F¼ 156.697*, P< 0.001*, R¼ 0.621, R2¼ 0.386
BMI, body mass index; CI, conﬁdence interval; PSA, prostate-speciﬁc antigen; SE,
standard error.
Prostate Int 4 (2016) 156e1591584. Discussion
The overall mean PSA in the present study was 3.02± 1.89 ng/
mL. Comparable levels were observed among Middle Eastern men
showing higher PSA with no evidence of prostate cancer. This was
attributed to increased incidence of BPH, alone or with concomitant
prostatitis.5
Our study showed that type 2 DM is associated with a signiﬁ-
cantly lower serum total PSA, than in nondiabetic individuals; a
ﬁnding that has been shown in other studies. This may be attrib-
uted to lower androgen levels found in diabetic men.3 Muller et al6
reported that men with elevated and highly elevated hemoglobin
A1c levels had 15% and 29% lower serum PSA levels, respectively.
Our results also suggested that men with type 2 DM have slower
increases in serum PSA levels over time. Similarly, Parekh et al7
reported lower prostate-cancer risk and serum PSA levels in later
stages of diabetes, which are characterized by insulin resistance
and lower levels of circulating insulin. Moreover, diabetes might
alter PSAvalues through impaired kidney function.8 Low serum PSA
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signiﬁcantly lower serum testosterone level inmenwith type 2 DM,
conﬁrming the direct role of hypogonadism in PSA values reported
by many authors.3,9,10 Accordingly, an endocrine society currently
recommends the measurement of testosterone in patients with
type 2 DM on a routine basis.11
Large prostate volume has been associated with components of
metabolic syndrome.12,13 This was consistent with our study, in
which a positive correlation between the duration of diabetes
treatment and prostate size was observed. In fact, both type 2 DM
and BPH seem to share similar epidemiological features, possibly
related to aging and diet.14 Barnard et al15 connected the reduction
of growth of stem epithelial prostate cells with the reduction of
insulin. Other possible mechanisms have been proposed to asso-
ciate the development of BPH with type 2 DM, such as the increase
in peripheral sympathetic nerve tone and activity of the autonomic
nervous system caused by hyperinsulinemia,16 and hypoxia caused
by DM-induced vascular damage.17
We have previously shown that high BMI is associated with the
same observed changes in prostate-related parameters.18 However,
in the present study, multiple regression analysis conﬁrmed that
type 2 DM was signiﬁcantly associated with a change in prostatic
parameters, independent from the effect of BMI.
We believe the importance of this study lies in studying the
effect of type 2 DM on the main parameters related to prostatic
growth, and being novel in correlating the effect of duration of DM
on these parameters.
A meta-analysis has proved the inverse correlation between DM
and prostate cancer.4 Baradaran et al19 studied 511 patients and
concluded that longer duration of DM may be protective against
prostate cancer. We did not study the association with prostate
cancer as an endpoint in our study. We tried to study how DM can
affect the prostate. This possibly refers to the protective effect
against prostate cancer or possibly just underdiagnosis of prostate
cancer in diabetic patients because of lower PSA and even larger
prostate volume that affects transrectal ultrasound biopsy out-
comes. Our study may extend further to hypothetically show that
diabetic patients may be liable to develop early castration-resistant
prostate cancer, due to larger prostate volume in the presence of
lower testosterone, pointing to the role of early androgen-
independent growth of the prostate. Many theories concerning
prostate cancer could be understood from this study, but will need
further studies to prove how practical they are.
In conclusion, patients with type 2 DM tend to have signiﬁcantly
lower serum total PSA, lower serum testosterone, and larger
prostate volume compared to nondiabetic individuals.
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